In Vitro Characterization of the Pyrazole-Carrying Synthetic Cannabinoid Receptor Agonist 5F-3,5-AB-PFUPPYCA and its Structural Analogs
Introduction: Pyrazole-carrying “FUPPYCA” synthetic cannabinoid receptor agonists (SCRAs) have made short-lived appearances on the market since 2015. However, 5F-3,5-AB-PFUPPYCA and 3,5-ADB-4en-PFUPPYCA have recently been detected in Scottish prisons. This re-emergence is believed to be triggered by...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-12-01
|
Series: | Emerging Trends in Drugs, Addictions, and Health |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2667118223000375 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1846123275183194112 |
---|---|
author | M.H. Deventer C. Norman R. Reid C. McKenzie N.N. Daeid C.P. Stove |
author_facet | M.H. Deventer C. Norman R. Reid C. McKenzie N.N. Daeid C.P. Stove |
author_sort | M.H. Deventer |
collection | DOAJ |
description | Introduction: Pyrazole-carrying “FUPPYCA” synthetic cannabinoid receptor agonists (SCRAs) have made short-lived appearances on the market since 2015. However, 5F-3,5-AB-PFUPPYCA and 3,5-ADB-4en-PFUPPYCA have recently been detected in Scottish prisons. This re-emergence is believed to be triggered by the Chinese generic SCRA ban (2021). Methods: Infused paper samples, seized from different Scottish prisons were analyzed to assess the prevalence of FUPPYCA SCRAs. Six structurally related analogs were then functionally characterized using live cell receptor-based assays, based on the functional complementation of a nanoluciferase enzyme. Results: 5F-3,5-AB-PFUPPYCA and 3,5-ADB-4en-PFUPPYCA mixtures were detected 9 times in Scottish prisons since July 2021. Most FUPPYCA SCRAs were found to be inactive at both CB1 and CB2, with only 3 analogs showing some (minor) CB1 activation potential (3,5-AB-CHMFUPPYCA, 5,3-AB-CHMFUPPYCA and 5,3-ADB-4en-PFUPPYCA). Interestingly, the 5,3 regioisomers (covered by the ban) were more active than their 3,5 counterparts. Furthermore, all analogs had antagonistic properties, potentially related to their structural resemblance to cannabinoid antagonists. Conclusions: Given their weak CB activity, FUPPYCA SCRAs are not expected to pose a serious health hazard, despite their ability to evade the generic ban. This may also explain their only transient re-emergence in Scottish prisons. |
format | Article |
id | doaj-art-8f5f96c2f63945ee9c35cd9776c58b3d |
institution | Kabale University |
issn | 2667-1182 |
language | English |
publishDate | 2024-12-01 |
publisher | Elsevier |
record_format | Article |
series | Emerging Trends in Drugs, Addictions, and Health |
spelling | doaj-art-8f5f96c2f63945ee9c35cd9776c58b3d2024-12-14T06:33:36ZengElsevierEmerging Trends in Drugs, Addictions, and Health2667-11822024-12-014100086In Vitro Characterization of the Pyrazole-Carrying Synthetic Cannabinoid Receptor Agonist 5F-3,5-AB-PFUPPYCA and its Structural AnalogsM.H. Deventer0C. Norman1R. Reid2C. McKenzie3N.N. Daeid4C.P. Stove5Ghent University, BelgiumGhent University, BelgiumGhent University, BelgiumGhent University, BelgiumGhent University, BelgiumGhent University, BelgiumIntroduction: Pyrazole-carrying “FUPPYCA” synthetic cannabinoid receptor agonists (SCRAs) have made short-lived appearances on the market since 2015. However, 5F-3,5-AB-PFUPPYCA and 3,5-ADB-4en-PFUPPYCA have recently been detected in Scottish prisons. This re-emergence is believed to be triggered by the Chinese generic SCRA ban (2021). Methods: Infused paper samples, seized from different Scottish prisons were analyzed to assess the prevalence of FUPPYCA SCRAs. Six structurally related analogs were then functionally characterized using live cell receptor-based assays, based on the functional complementation of a nanoluciferase enzyme. Results: 5F-3,5-AB-PFUPPYCA and 3,5-ADB-4en-PFUPPYCA mixtures were detected 9 times in Scottish prisons since July 2021. Most FUPPYCA SCRAs were found to be inactive at both CB1 and CB2, with only 3 analogs showing some (minor) CB1 activation potential (3,5-AB-CHMFUPPYCA, 5,3-AB-CHMFUPPYCA and 5,3-ADB-4en-PFUPPYCA). Interestingly, the 5,3 regioisomers (covered by the ban) were more active than their 3,5 counterparts. Furthermore, all analogs had antagonistic properties, potentially related to their structural resemblance to cannabinoid antagonists. Conclusions: Given their weak CB activity, FUPPYCA SCRAs are not expected to pose a serious health hazard, despite their ability to evade the generic ban. This may also explain their only transient re-emergence in Scottish prisons.http://www.sciencedirect.com/science/article/pii/S2667118223000375 |
spellingShingle | M.H. Deventer C. Norman R. Reid C. McKenzie N.N. Daeid C.P. Stove In Vitro Characterization of the Pyrazole-Carrying Synthetic Cannabinoid Receptor Agonist 5F-3,5-AB-PFUPPYCA and its Structural Analogs Emerging Trends in Drugs, Addictions, and Health |
title | In Vitro Characterization of the Pyrazole-Carrying Synthetic Cannabinoid Receptor Agonist 5F-3,5-AB-PFUPPYCA and its Structural Analogs |
title_full | In Vitro Characterization of the Pyrazole-Carrying Synthetic Cannabinoid Receptor Agonist 5F-3,5-AB-PFUPPYCA and its Structural Analogs |
title_fullStr | In Vitro Characterization of the Pyrazole-Carrying Synthetic Cannabinoid Receptor Agonist 5F-3,5-AB-PFUPPYCA and its Structural Analogs |
title_full_unstemmed | In Vitro Characterization of the Pyrazole-Carrying Synthetic Cannabinoid Receptor Agonist 5F-3,5-AB-PFUPPYCA and its Structural Analogs |
title_short | In Vitro Characterization of the Pyrazole-Carrying Synthetic Cannabinoid Receptor Agonist 5F-3,5-AB-PFUPPYCA and its Structural Analogs |
title_sort | in vitro characterization of the pyrazole carrying synthetic cannabinoid receptor agonist 5f 3 5 ab pfuppyca and its structural analogs |
url | http://www.sciencedirect.com/science/article/pii/S2667118223000375 |
work_keys_str_mv | AT mhdeventer invitrocharacterizationofthepyrazolecarryingsyntheticcannabinoidreceptoragonist5f35abpfuppycaanditsstructuralanalogs AT cnorman invitrocharacterizationofthepyrazolecarryingsyntheticcannabinoidreceptoragonist5f35abpfuppycaanditsstructuralanalogs AT rreid invitrocharacterizationofthepyrazolecarryingsyntheticcannabinoidreceptoragonist5f35abpfuppycaanditsstructuralanalogs AT cmckenzie invitrocharacterizationofthepyrazolecarryingsyntheticcannabinoidreceptoragonist5f35abpfuppycaanditsstructuralanalogs AT nndaeid invitrocharacterizationofthepyrazolecarryingsyntheticcannabinoidreceptoragonist5f35abpfuppycaanditsstructuralanalogs AT cpstove invitrocharacterizationofthepyrazolecarryingsyntheticcannabinoidreceptoragonist5f35abpfuppycaanditsstructuralanalogs |